Gastrointestinal cancer 1（肝胆膵）| Discussion・Q&A

解説【LBA50】IMbrave152/SKYSCRAPER-14: a phase 3 study of first-line tiragolumab (tira) + atezolizumab (atezo)+ bevacizumab (bev) vs placebo (pbo) + atezo + bev for patients (pts) with untreated locally advanced or metastatic hepatocellular carcinoma (HCC)

今岡 大
（国立がん研究センター東病院）

解説【LBA51】IKF-035/ABC-HCC: A Phase IIIb, randomized, multicenter, open-label trial of Atezolizumab plus Bevacizumab versus transarterial Chemoembolization (TACE) in intermediate-stage HepatoCellular Carcinoma

今岡 大
（国立がん研究センター東病院）

解説【LBA84】Efficacy and safety of GFH375 monotherapy in previously treated advanced KRAS G12D-mutant pancreatic ductal adenocarcinoma (PDAC)

今岡 大
（国立がん研究センター東病院）

解説【916O】Preliminary Phase 1 Results of INCB161734, A Novel Oral KRAS G12D Inhibitor, In Patients With Advanced or Metastatic Solid Tumors

今岡 大
（国立がん研究センター東病院）

解説【2215O】HRS-4642 combined with gemcitabine and nab-paclitaxel in KRAS-G12D mutant advanced pancreatic cancer: A phase Ib/II study

今岡 大
（国立がん研究センター東病院）